Long-term safety and erythroid response with luspatercept treatment in patients with ß-thalassemia.

Piga, Antonio; Longo, Filomena; Gamberini, Maria Rita; Voskaridou, Ersi; Ricchi, Paolo; Caruso, Vincenzo; Pietrangelo, Antonello; Zhang, Xiaosha; Shetty, Jeevan K; Attie, Kenneth M; Tartaglione, Immacolata

Piga, Antonio; Longo, Filomena; Gamberini, Maria Rita; Voskaridou, Ersi; Ricchi, Paolo; Caruso, Vincenzo; Pietrangelo, Antonello; Zhang, Xiaosha; Shetty, Jeevan K; Attie, Kenneth M; Tartaglione, Immacolata.

Afiliación

Piga A; Department of Clinical and Biological Sciences, Turin University, Regione Gonzole, 10, Orbassano, 10043 Turin, Italy.
Longo F; Department of Clinical and Biological Sciences, Turin University, Turin, Italy.
Gamberini MR; Thalassemia Unit, Arcispedale S. Anna, Ferrara, Italy.
Voskaridou E; Thalassemia and Sickle Cell Center, Laiko General Hospital, Athens, Greece.
Ricchi P; Malattie Rare Del Globulo Rosso, AORN Cardarelli, Naples, Italy.
Caruso V; ARNAS Garibaldi, Catania, Italy.
Pietrangelo A; CEMEF, Medicina 2, Modena, Italy.
Zhang X; Formerly Acceleron Pharma, Cambridge, MA, USA.
Shetty JK; Celgene International Sàrl, Bristol-Myers Squibb Company, Boudry, Switzerland.
Attie KM; Formerly Acceleron Pharma, Cambridge, MA, USA.
Tartaglione I; Università della Campania "L. Vanvitelli", Naples, Italy.

Ther Adv Hematol ; 13: 20406207221134404, 2022.

Article en En | MEDLINE | ID: mdl-36505885

Palabras clave

anemia; luspatercept; thalassemia

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Ther Adv Hematol Año: 2022 Tipo del documento: Article País de afiliación: Italia

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google